The Latest in FDA Evaluations and Research

FDA News


Related Topics: FDA News, Sarbanes Oxley on Ulitzer

News Feed Item

iCAD Expands Partnership with Volpara Solutions to Offer Enhanced Breast Imaging Analytics for 2D Mammography and Tomosynthesis

New additions to PowerLook AMP provide radiologists a consistent, standardized way to evaluate performance of breast imaging systems in real time

NASHUA, N.H., Sept. 4, 2014 /PRNewswire/ -- iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that, in addition to Volpara®Density volumetric breast density assessment software, Volpara®Analytics and Volpara®Dosesolutions are now available as part of iCAD's PowerLook Advanced Mammography Platform (AMP)®. With the addition of these quantitative breast imaging tools, radiologists will be able to evaluate the performance of all major digital mammography and tomosynthesis units and obtain patient-specific dose information to make informed treatment decisions in real time.

"Today's healthcare environment is increasingly data-driven and our customers require up-to-the-minute access to analytics that impact patient care," said Ken Ferry, CEO of iCAD. "By incorporating additional breast imaging analytic and reporting solutions from Volpara, our PowerLook AMP customers will be able to go beyond automated mammography unit settings and mine patient-specific, real-time information for actionable insights regarding care delivery within their practices and across patient populations."

PowerLook AMP is a next-generation digital mammography computer-aided detection (CAD) platform that provides radiologists with the ability to customize their 2D CAD solution to meet the needs of their individual work environment. Now with the option to incorporate VolparaAnalytics and VolparaDose in addition to VolparaDensity, PowerLook AMP users will, among other benefits, be able to:

  • Improve patient safety and reporting through personalized measurements of density, patient dose, breast compression and other volumetric factors designed to help maintain accuracy and consistent quality in breast screening.
  • Optimize performance/utilization of staff and mammography systems.
  • Utilize a globally-accepted algorithm incorporating breast density to generate patient-specific radiation dose estimates, which can be automatically entered in patient communications.

"The PowerLook AMP platform has gained a well-established user base and is now considered a key clinical decision support technology in thousands of mammography suites," said Ralph Highnam, PhD, CEO of Volpara Solutions. "The addition of Volpara's dose and analytics tools to the suite is a natural fit that will only enhance the value of this technology to customers. We are proud to continue our collaboration with iCAD to help address the specialized diagnostic needs of the radiology practice."

Cleared by the FDA, HealthCanada, the TGA and CE-marked, VolparaDensity is used by radiologists to objectively assess density from both digital mammography and tomosynthesis images to help doctors evaluate who might benefit from additional screening.  Highly correlated to breast MR assessments, VolparaDensity is a reliable tool that automatically generates an objective measurement of volumetric breast density correlated to the ACR (American College of Radiology) breast density categories.  To date, more than 3 million women have had their breast density analyzed using VolparaDensity. 

For additional information regarding PowerLook AMP and these newly available features, please visit www.icadmed.com/volparasolutions.html.

About iCAD, Inc.
iCAD is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging for breast and prostate cancers, and Computed Tomography for colorectal cancer.  iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and gynecological cancers. For more information, call 877-iCADnow, or visit www.icadmed.com.

About Volpara Solutions
Founded to enable radiologists to give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Matakina Technology Limited of New Zealand. Matakina's founders and Board of Directors include John Hood, PhD, former Vice Chancellor of the University of Oxford, UK; Ralph Highnam, PhD, former CEO of Mirada Solutions, one of the University of Oxford's most successful spin-outs of recent times and co-author of the seminal book Mammographic Image Analysis; and Professor Sir Michael Brady, a serial entrepreneur who recently retired from the University of Oxford where he was Professor of Information Technology for 25 years.

For iCAD investor relations, contact Anne Marie Fields of LHA at 212-838-3777 x6604 or via email at [email protected]

For iCAD media inquiries, contact Lynn Granito of Berry & Company at 212-253-8881 or via email at [email protected]

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company's significant losses and uncertainty of our ability to achieve and sustain profitability, the ability to protect patents and other proprietary rights, the ability to defend itself in litigation matters, the Company's customers' ability to obtain appropriate coverage, and reimbursement from third-party payors, for our products and treatments, the Company's ability to create significant markets for its newly developed products and treatments, the Company's dependence on a limited number of customers, the uncertainty of growth of the Company's product markets, the risk of impairment of the Company's goodwill or other intangible assets, the risks related to regulatory and other legal requirements, the significant costs of extensive regulatory compliance, the volatility of the Company's operating and financial results, the risks related to the Company's existing and future debt obligations, the possible technological obsolescence of the Company's products, the impact of supply and manufacturing constraints or difficulties, competitive pressures and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov

SOURCE iCAD, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.